Home › Acute Myeloid Leukemia › New Jersey › Newark
Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Newark, NJ
Isang pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Newark. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Nagre-recruitPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi ang layo
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Morristown Medical Center, Morristown · 17 mi ang layo
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi ang layo
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi ang layo
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi ang layo
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi ang layo
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Nagre-recruitPhase 3
- Newark Beth Israel Medical Center, Newark
- Morristown Medical Center, Morristown · 17 mi ang layo
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
- Atlantic Health, Morristown · 17 mi ang layo
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Nagre-recruitPhase 1/2
- Morristown Medical Center, Morristown · 17 mi ang layo
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Nagre-recruitPhase 3
- Morristown Medical Center, Morristown · 17 mi ang layo
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Nagre-recruitPhase 2/3
- Atlantic Health, Morristown · 17 mi ang layo
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Nagre-recruitPhase 1/2
- Atlantic Health, Morristown · 17 mi ang layo
Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod
- Houston, TX85 pag-aaral
- New York City, NY51 pag-aaral
- Boston, MA44 pag-aaral
- Seattle, WA41 pag-aaral
- Baldwin Park, CA40 pag-aaral
- Columbus, OH35 pag-aaral
- Philadelphia, PA34 pag-aaral
- Durham, NC33 pag-aaral
- Atlanta, GA31 pag-aaral
- Tampa, FL29 pag-aaral
- Chicago, IL26 pag-aaral
- Portland, OR25 pag-aaral
Iba pang pag-aaral sa Newark
- Kanser sa Suso18 pag-aaral
- Pinsala sa Spinal Cord13 pag-aaral
- Non-Small Cell Lung Cancer13 pag-aaral
- Pagkabigo ng Puso10 pag-aaral
- Metastatic Cancer10 pag-aaral
- Sakit sa Puso at Ugat ng Dugo9 pag-aaral
- Kanser sa Pancreas9 pag-aaral
- Melanoma8 pag-aaral
- Kanser (lahat ng uri)7 pag-aaral
- Kanser sa Baga7 pag-aaral
- Crohn's Disease7 pag-aaral
- Stenosis ng Aortic Valve6 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.